Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 20/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 19/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 9/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 9/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.39 |
| ▸ | USP2 | O75604 | 5/20 | 0.39 |
| ▸ | TSHR | P16473 | 5/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 7/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.37 |
| ▸ | LMNA | P02545 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 6/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12615035 | 0.74 | CYP3A4 (0.38) | CYP3A4CYP1A2CYP2D6CLK4ALDH1A1 | |
| SCHEMBL1788256 | 0.74 | CYP3A4 (0.38) | CYP3A4CYP1A2CYP2D6CLK4ALDH1A1 | |
| SCHEMBL12651968 | 0.71 | HSP90AA1 (0.43) | ALDH1A1MEN1KMT2AHPGDTDP1 | |
| SCHEMBL3804748 | 0.63 | HSP90AA1 (0.47) | — | |
| SCHEMBL1610087 | 0.60 | PDE10A (0.47) | CYP3A4CYP1A2CYP2D6CLK4ALDH1A1 | |
| SCHEMBL22249592 | 0.59 | NLRP3 (0.67) | CYP3A4CYP1A2CYP2D6CLK4ALDH1A1 | |
| SCHEMBL3984933 | 0.59 | CYP1A2 (0.42) | CYP3A4CYP1A2CYP2D6CLK4ALDH1A1 | |
| SCHEMBL29454108 | 0.58 | CYP1A2 (0.42) | CYP3A4CYP1A2CYP2D6CLK4ALDH1A1 | |
| SCHEMBL22232418 | 0.58 | CYP1A2 (0.42) | CYP3A4CYP1A2CYP2D6CLK4ALDH1A1 | |
| SCHEMBL27737203 | 0.57 | CYP1A2 (0.39) | CYP3A4CYP1A2CYP2D6CLK4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110124634-A1 | BIOACTIVE COMPOUNDS FOR TREATMENT OF CANCER AND NEURODEGENERATIVE DISEASES | PONIARD PHARMACEUTICALS, INC. | 2011-05-26 | — | — | US | disclosed |
| WO-2009139834-A1 | BIOACTIVE COMPOUNDS FOR TREATMENT OF CANCER AND NEURODEGENERATIVE DISEASES | PONIARD PHARMACEUTICALS, INC. (US) | 2009-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124634-A1 | BIOACTIVE COMPOUNDS FOR TREATMENT OF CANCER AND NEURODEGENERATIVE DISEASES | PARK7, BDNF, BACE1 | CYP3A4 3266/4885CYP1A2 3248/4885CYP2D6 3167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.